Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival.
Tumor size predicts disease-specific survival in patients with primary disease who undergo complete gross resection and investigational protocols are indicated to reduce the rate of recurrence after resections and to improve the outcome for patients with GIST.
NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors.
- G. Demetri, M. von Mehren, J. Wayne
- MedicineThe Journal of the National Comprehensive Cancer…
- 1 April 2010
The standard of care for managing patients with gastrointestinal stromal tumors (GISTs) rapidly changed after the introduction of effective molecularly targeted therapies involving tyrosine kinase…
Staging, Resectability, and Outcome in 225 Patients With Hilar Cholangiocarcinoma
By taking full account of local tumor extent, the proposed staging system for hilar cholangiocarcinoma accurately predicts resectability, the likelihood of metastatic disease, and survival.
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
Analysis of advanced cancer patients treated with immune-checkpoint inhibitors shows that tumor mutational burden, as assessed by targeted next-generation sequencing, predicts survival after immunotherapy across multiple cancer types.
Posthepatectomy liver failure: a definition and grading by the International Study Group of Liver Surgery (ISGLS).
Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial
Improvement in Perioperative Outcome After Hepatic Resection: Analysis of 1,803 Consecutive Cases Over the Past Decade
The number of hepatic segments resected and operative blood loss were the only independent predictors of both perioperative morbidity and mortality, and reductions in both are largely responsible for the decrease in peri operative mortality, which has occurred despite an increase in concomitant major procedures.
Intrahepatic Cholangiocarcinoma: Rising Frequency, Improved Survival, and Determinants of Outcome After Resection
At Memorial Sloan-Kettering Cancer Center, intrahepatic cholangiocarcinoma incidence has increased dramatically in the last 16 years and the recent increase in survival seems largely because of improved nonoperative therapy for unresectable disease.
Imatinib potentiates anti-tumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido
It is found that the immune system contributes substantially to the antitumor effects of imatinib in GIST, and concomitant immunotherapy may further improve outcomes in human cancers treated with targeted agents.
Acquired Resistance to Imatinib in Gastrointestinal Stromal Tumor Occurs Through Secondary Gene Mutation
That acquired resistance to imatinib in GIST commonly occurs via secondary gene mutation in the KIT kinase domain has implications for strategies to delay or preventImatinib resistance and to employ newer targeted therapies.